Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Published version of a preprint
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose: Recombinant Listeria vaccines induce tumor-specific T-cell responses that eliminate established tumors and prevent metastatic disease in murine cancer models. We used dogs with HER2/neu+ appendicular osteosarcoma, a well-recognized spontaneous model for pediatric osteosarcoma, to determine whether a highly attenuated, recombinant Listeria monocytogenes expressing a chimeric human HER2/neu fusion protein (ADXS31-164) could safely induce HER2/neu-specific immunity and prevent metastatic disease. Experimental Design: Eighteen dogs that underwent limb amputation or salvage surgery and adjuvant chemotherapy were enrolled in a phase I dose escalation clinical trial and received either 2 × 108, 5 × 108, 1 × 109, or 3.3 × 109 CFU of ADXS31-164 intravenously every 3 weeks for 3 administrations. Results: Only low-grade, transient toxicities were observed. ADXS31-164 broke peripheral tolerance and induced antigen-specific IFNγ responses against the intracellular domain of HER2/neu in 15 of 18 dogs within 6 months of treatment. Furthermore, ADXS31-164 reduced the incidence of metastatic disease and significantly increased duration of survival time and 1-, 2-, and 3-year survival rates when compared with a historical control group with HER2/neu+ appendicular osteosarcoma treated with amputation and chemotherapy alone. Conclusions: These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease can induce HER2/neu-specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings, therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu+ cancers. Clin Cancer Res; 22(17); 4380–90. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They found that ADXS31-164 induced HER2/neu-specifific immunity and reduced the incidence of metastatic disease and prolonged OS [148].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [148]
In the citing paper
“Similar approaches have used engineered Listeria bacteria to reprogramme macrophages while also eliciting adaptive responses to the potential tumour antigen HER2, an approach that has suggested increased event-free survival in early-phase canine osteosarcoma trials 69 .”
From Osteosarcoma (2022) · cites this paper as [69]
In the citing paper
“This integrated approach has been particularly promising for the evaluation of anti-metastatic 99,234 and immune-based therapeutics 69,235 .”
From Osteosarcoma (2022) · cites this paper as [69]
Citations
Cites
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Allometric Scaling of M-Mode Cardiac Measurements in Normal Adult Dogs
Cornell, C. C., Kittleson, M. D., Torre, P. D., Häggström, J., Lombard, C. W., Pedersen, H. D., Vollmar, A., & Wey, A. (2004) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2004.tb02551.x · Cited by 811
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“Osteosarcoma is considered an immunologically responsive tumor and dogs with spontaneous osteosarcoma can be used to evaluate the effectiveness of immunotherapy to prevent metastases and subsequently inform human clinical trials (3, 7, 36, 37).”
BackgroundHER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Maciag, P. C., Radulovic, S., & Rothman, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.041 · Cited by 324
Osteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
Paoloni, M., Davis, S., Lana, S., Withrow, S., Sangiorgi, L., Picci, P., Hewitt, S., Triche, T., Meltzer, P., & Khanna, C. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-625 · Cited by 291
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Osteosarcoma: a comprehensive review
Misaghi, A., Goldin, A., Awad, M., & Kulidjian, A. A. (2018) · SICOT-J · doi:10.1051/sicotj/2017028 · Cited by 517
“made promising strides in a canine model of OS, using an attenuated listeria vaccine to deliver and induce innate HER2/neu immunity, leading to a significant reduction in metastatic disease and increases in survival [86].”
BackgroundEmerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Simpson, S., Dunning, M. D., de Brot, S., Grau-Roma, L., Mongan, N. P., & Rutland, C. S. (2017) · Acta Veterinaria Scandinavica · doi:10.1186/s13028-017-0341-9 · Cited by 284
“More recent reports on the use of immunotherapy based on an attenuated recombinant Listeria monocyotogenes expressing a chimeric HERS/neu fusion protein have shown some encouraging results [72].”
Result
Metadata
- Authors
- Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y.
- Affiliations
- University of Pennsylvania (US)
- Drexel University (US)
- Advaxis (United States) (US)
- 5ClinData Services Inc., Fort Collins, Colorado.
- Venue
- Clinical Cancer Research
- Published
- 2016-08-31
- Volume
- 22
- Issue
- 17
- Pages
- 4380-4390
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2328995829
- Cited by
- 178
- References
- 45
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 11 · 2023: 20 · 2022: 16 · 2021: 24 · 2020: 20 · 2019: 30 · 2018: 19 · 2017: 7 · 2016: 3
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- HER2/neu, osteosarcoma, Listeria monocytogenes vaccine, adoptive immunotherapy, canine model, metastasis prevention, tumor-specific T cell responses, interferon-gamma, survival, pediatric osteosarcoma, dose escalation
- MeSH terms
- Animals, Bone Neoplasms, Dog Diseases, Dogs, Immunity, Cellular, Immunization Schedule, Immunotherapy, Interferon-gamma, Listeria, Osteosarcoma, Vaccination, Vaccines, Synthetic, Biomarkers, Treatment Outcome, Disease Progression, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0088
- The paper
- Mason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016). Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0088
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.